Oncolytics Biotech (ONCY) Competitors $1.04 -0.03 (-2.80%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$1.06 +0.01 (+1.44%) As of 08/29/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ONCY vs. AQST, OLMA, RCKT, YMAB, VIGL, ATXS, FULC, ABEO, INBX, and ADCTShould you be buying Oncolytics Biotech stock or one of its competitors? The main competitors of Oncolytics Biotech include Aquestive Therapeutics (AQST), Olema Pharmaceuticals (OLMA), Rocket Pharmaceuticals (RCKT), Y-mAbs Therapeutics (YMAB), Vigil Neuroscience (VIGL), Astria Therapeutics (ATXS), Fulcrum Therapeutics (FULC), Abeona Therapeutics (ABEO), Inhibrx Biosciences (INBX), and ADC Therapeutics (ADCT). These companies are all part of the "pharmaceutical products" industry. Oncolytics Biotech vs. Its Competitors Aquestive Therapeutics Olema Pharmaceuticals Rocket Pharmaceuticals Y-mAbs Therapeutics Vigil Neuroscience Astria Therapeutics Fulcrum Therapeutics Abeona Therapeutics Inhibrx Biosciences ADC Therapeutics Aquestive Therapeutics (NASDAQ:AQST) and Oncolytics Biotech (NASDAQ:ONCY) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, risk, analyst recommendations, media sentiment, earnings, valuation, profitability and institutional ownership. Which has more risk & volatility, AQST or ONCY? Aquestive Therapeutics has a beta of 1.82, suggesting that its share price is 82% more volatile than the S&P 500. Comparatively, Oncolytics Biotech has a beta of 1.19, suggesting that its share price is 19% more volatile than the S&P 500. Do analysts rate AQST or ONCY? Aquestive Therapeutics presently has a consensus price target of $10.14, suggesting a potential upside of 169.04%. Oncolytics Biotech has a consensus price target of $5.00, suggesting a potential upside of 380.77%. Given Oncolytics Biotech's higher probable upside, analysts clearly believe Oncolytics Biotech is more favorable than Aquestive Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aquestive Therapeutics 0 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.88Oncolytics Biotech 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80 Which has stronger valuation and earnings, AQST or ONCY? Oncolytics Biotech has lower revenue, but higher earnings than Aquestive Therapeutics. Aquestive Therapeutics is trading at a lower price-to-earnings ratio than Oncolytics Biotech, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAquestive Therapeutics$57.56M6.53-$44.14M-$0.70-5.39Oncolytics BiotechN/AN/A-$23.14M-$0.27-3.85 Does the media refer more to AQST or ONCY? In the previous week, Aquestive Therapeutics had 1 more articles in the media than Oncolytics Biotech. MarketBeat recorded 6 mentions for Aquestive Therapeutics and 5 mentions for Oncolytics Biotech. Aquestive Therapeutics' average media sentiment score of 1.25 beat Oncolytics Biotech's score of 0.71 indicating that Aquestive Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aquestive Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Oncolytics Biotech 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is AQST or ONCY more profitable? Oncolytics Biotech has a net margin of 0.00% compared to Aquestive Therapeutics' net margin of -147.38%. Aquestive Therapeutics' return on equity of 0.00% beat Oncolytics Biotech's return on equity.Company Net Margins Return on Equity Return on Assets Aquestive Therapeutics-147.38% N/A -63.87% Oncolytics Biotech N/A -438.11%-143.90% Do institutionals & insiders have more ownership in AQST or ONCY? 32.5% of Aquestive Therapeutics shares are held by institutional investors. Comparatively, 6.8% of Oncolytics Biotech shares are held by institutional investors. 7.9% of Aquestive Therapeutics shares are held by insiders. Comparatively, 0.1% of Oncolytics Biotech shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. SummaryAquestive Therapeutics beats Oncolytics Biotech on 10 of the 14 factors compared between the two stocks. Get Oncolytics Biotech News Delivered to You Automatically Sign up to receive the latest news and ratings for ONCY and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ONCY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ONCY vs. The Competition Export to ExcelMetricOncolytics BiotechMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$104.38M$3.07B$5.75B$9.76BDividend YieldN/A2.29%4.08%4.04%P/E Ratio-3.8520.7883.2726.60Price / SalesN/A386.53541.17113.73Price / CashN/A44.2237.4459.26Price / Book20.808.0710.556.58Net Income-$23.14M-$53.98M$3.27B$265.95M7 Day Performance2.97%-0.88%0.40%0.17%1 Month Performance1.96%7.72%7.31%3.90%1 Year Performance8.45%7.03%46.58%19.67% Oncolytics Biotech Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ONCYOncolytics Biotech1.7508 of 5 stars$1.04-2.8%$5.00+380.8%+8.4%$104.38MN/A-3.8530AQSTAquestive Therapeutics2.0363 of 5 stars$3.86-3.0%$10.14+162.8%-16.8%$396.90M$57.56M-5.51160Positive NewsOLMAOlema Pharmaceuticals2.0335 of 5 stars$5.59-3.0%$24.00+329.3%-53.7%$395.33MN/A-2.8270News CoverageRCKTRocket Pharmaceuticals4.9013 of 5 stars$3.54-2.7%$16.73+372.7%-82.6%$392.77MN/A-1.41240YMABY-mAbs Therapeutics2.4635 of 5 stars$8.52-0.1%$9.62+12.9%-40.3%$387.59M$87.68M-17.04150Positive NewsVIGLVigil Neuroscience1.3003 of 5 stars$8.05flat$10.80+34.2%N/A$383.91MN/A-3.9340ATXSAstria Therapeutics2.5795 of 5 stars$6.42-5.4%$29.00+351.7%-49.5%$383.19MN/A-3.1930News CoverageFULCFulcrum Therapeutics0.9387 of 5 stars$6.41-6.8%$7.57+18.1%-24.2%$372.15M$80M-5.25100ABEOAbeona Therapeutics4.3597 of 5 stars$7.01-3.0%$19.50+178.2%+19.8%$370.74M$3.50M10.0190News CoverageINBXInhibrx Biosciences1.5903 of 5 stars$25.04+0.2%N/A+93.7%$362.14M$200K0.00166ADCTADC Therapeutics1.2937 of 5 stars$3.09-3.0%$7.75+151.2%+6.0%$357.75M$70.84M0.00310 Related Companies and Tools Related Companies Aquestive Therapeutics Competitors Olema Pharmaceuticals Competitors Rocket Pharmaceuticals Competitors Y-mAbs Therapeutics Competitors Vigil Neuroscience Competitors Astria Therapeutics Competitors Fulcrum Therapeutics Competitors Abeona Therapeutics Competitors Inhibrx Biosciences Competitors ADC Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ONCY) was last updated on 8/31/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oncolytics Biotech Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Oncolytics Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
